| Trial ID: | L2483 |
| Source ID: | NCT00811460
|
| Associated Drug: |
Placebo
|
| Title: |
A Study of Taspoglutide in Type 2 Diabetic Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: Placebo|DRUG: taspoglutide|DRUG: taspoglutide
|
| Outcome Measures: |
Primary: Incremental area under insulin concentration time curve relative to basal insulin concentration, First 10 minutes after glucose bolus | Secondary: Incremental area under insulin concentration time curve relative to basal insulin concentration, 10-120 minutes after glucose bolus|Adverse events, laboratory parameters, Throughout study
|
| Sponsor/Collaborators: |
Sponsor: Hoffmann-La Roche
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-11
|
| Completion Date: |
2009-08
|
| Results First Posted: |
|
| Last Update Posted: |
2016-11-02
|
| Locations: |
Neuss, 41460, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT00811460
|
